Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer

This prospective study was conducted with the Korean Cancer Study Group to evaluate the efficacy and safety of cetuximab combined with modified FOLFOX6 (mFOLFOX6) as first-line treatment in recurrent or metastatic gastric cancer and to identify potential predictive biomarkers. Patients received cetu...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, S-W, Oh, D-Y, Im, S-A, Park, S R, Lee, K-W, Song, H S, Lee, N-S, Lee, K H, Choi, I S, Lee, M H, Kim, M A, Kim, W H, Bang, Y-J, Kim, T-Y
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2634707/
https://www.ncbi.nlm.nih.gov/pubmed/19127259
http://dx.doi.org/10.1038/sj.bjc.6604861

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2634707/
https://www.ncbi.nlm.nih.gov/pubmed/19127259
http://dx.doi.org/10.1038/sj.bjc.6604861

Ejemplares similares